Microporous polysaccharide hemosphere absorbable hemostat use in cardiothoracic surgical procedures

Brian A. Bruckner, Lance N. Blau, Limael Rodriguez, Erik E. Suarez, Uy Q. Ngo, Michael J. Reardon, Matthias Loebe

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


Background: Topical hemostatic agents are used to reduce bleeding and transfusion need during cardiothoracic surgery. We report our experience with Arista® AH Absorbable Hemostatic Particles (Arista® AH), a novel plant-based microporous polysaccharide hemostatic powder. Methods: Data were retrospectively collected for patients (n=240) that received cardiothoracic surgery at our institution from January 2009 to January 2013 with (n=103) or without (n=137) the use of Arista® AH. Endpoints included protamine to skin closure time (hemostasis time), cardiopulmonary bypass time, quantity of Arista® AH applied, intraoperative blood product usage, intraoperative blood loss, chest tube output 48 hours postoperatively, blood products required 48hours postoperatively, length of stay in the intensive care unit, 30-day morbidity, and 30-day mortality. Results: 240 patients (176M: 64F) underwent 240 cardiothoracic procedures including heart transplantation (n=53), cardiac assist devices (n=113), coronary artery bypass grafts (n=20), valve procedures (n=19), lung transplantation (n=17), aortic dissection (n=8), and other (n=10). Application of Arista® AH led to significant reduction in hemostasis time versus the untreated control group (Arista® AH: 93.4±41min. vs. Control: 107.6±56min., p=0.02). Postoperative chest tube output in the first 48hours was also significantly reduced (Arista® AH: 1594±949mL vs. Control: 2112± 1437mL, p<0.001), as well as transfusion of packed red blood cells (Arista® AH: 2.4± 2.5 units vs. Control: 4.0±5.1 units, p<0.001). There was no significant difference in 30-day mortality or postoperative complications. Conclusion: Use of Arista® AH in complex cardiothoracic surgery resulted in a significant reduction in hemostasis time, postoperative chest tube output, and need for postoperative blood transfusion.

Original languageEnglish (US)
Article number134
JournalJournal of Cardiothoracic Surgery
Issue number1
StatePublished - Aug 2 2014


  • Biomaterials
  • Bleeding control
  • Coagulants

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Microporous polysaccharide hemosphere absorbable hemostat use in cardiothoracic surgical procedures'. Together they form a unique fingerprint.

Cite this